Literature DB >> 7616230

Phosphatase activity toward abnormally phosphorylated tau: decrease in Alzheimer disease brain.

C X Gong1, S Shaikh, J Z Wang, T Zaidi, I Grundke-Iqbal, K Iqbal.   

Abstract

Microtubule-associated protein tau is abnormally hyperphosphorylated and aggregated in affected neurons of Alzheimer disease brain. This hyperphosphorylated tau can be dephosphorylated at some of the abnormal phosphorylated sites by purified protein phosphatase-1, 2A, and 2B in vitro. In the present study, we have developed an assay to measure protein phosphatase activity toward tau-1 sites (Ser199/Ser202) using the hyperphosphorylated tau isolated from Alzheimer disease brain as substrate. Using this assay, we have identified that in normal brain, protein phosphatase-2A and 2B and, to a lesser extent, 1 are involved in the dephosphorylation of tau. The Km values of dephosphorylation of the hyperphosphorylated tau by protein phosphatase-2A and 2B are similar. The tau phosphatase activity is decreased by approximately 30% in brain of Alzheimer disease patients compared with those of age-matched controls. These findings suggest that a defect of protein phosphatase could be the cause of the abnormal hyperphosphorylation of tau in Alzheimer disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7616230     DOI: 10.1046/j.1471-4159.1995.65020732.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  152 in total

1.  Multiple forms of phosphatase from human brain: isolation and partial characterization of affi-gel blue binding phosphatases.

Authors:  L Y Cheng; J Z Wang; C X Gong; J J Pei; T Zaidi; I Grundke-Iqbal; K Iqbal
Journal:  Neurochem Res       Date:  2000-01       Impact factor: 3.996

2.  Okadaic acid induces tau phosphorylation in SH-SY5Y cells in an estrogen-preventable manner.

Authors:  Zhang Zhang; James W Simpkins
Journal:  Brain Res       Date:  2010-05-07       Impact factor: 3.252

Review 3.  Targeting tau protein in Alzheimer's disease.

Authors:  Cheng-Xin Gong; Inge Grundke-Iqbal; Khalid Iqbal
Journal:  Drugs Aging       Date:  2010-05       Impact factor: 3.923

4.  CD45 opposes beta-amyloid peptide-induced microglial activation via inhibition of p44/42 mitogen-activated protein kinase.

Authors:  J Tan; T Town; T Mori; Y Wu; M Saxe; F Crawford; M Mullan
Journal:  J Neurosci       Date:  2000-10-15       Impact factor: 6.167

5.  Pseudohyperphosphorylation has differential effects on polymerization and function of tau isoforms.

Authors:  Benjamin Combs; Kellen Voss; T Chris Gamblin
Journal:  Biochemistry       Date:  2011-10-17       Impact factor: 3.162

Review 6.  Current therapeutic targets for the treatment of Alzheimer's disease.

Authors:  Joshua D Grill; Jeffrey L Cummings
Journal:  Expert Rev Neurother       Date:  2010-05       Impact factor: 4.618

7.  Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models.

Authors:  Janet van Eersel; Yazi D Ke; Xin Liu; Fabien Delerue; Jillian J Kril; Jürgen Götz; Lars M Ittner
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-19       Impact factor: 11.205

Review 8.  Tau pathology generated by overexpression of tau.

Authors:  I Grundke-Iqbal; K Iqbal
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

Review 9.  Hyperphosphorylated tau is implicated in acquired epilepsy and neuropsychiatric comorbidities.

Authors:  Ping Zheng; Sandy R Shultz; Chris M Hovens; Dennis Velakoulis; Nigel C Jones; Terence J O'Brien
Journal:  Mol Neurobiol       Date:  2013-12-10       Impact factor: 5.590

Review 10.  Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease.

Authors:  C-X Gong; K Iqbal
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.